A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

PHASE1CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

May 27, 2024

Study Completion Date

April 15, 2025

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
DRUG

Irinotecan liposome injection

Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)

DRUG

Irinotecan liposome injection

Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)

DRUG

Irinotecan liposome injection

Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)

DRUG

Irinotecan liposome injection

Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)

DRUG

Folinic Acid

LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle

DRUG

5-Fluorouracil

5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle

Trial Locations (36)

22763

Asklepios Klinik Altona, Hamburg

28034

Hospital Universitario Ramon Y Cajal, Madrid

28223

Hospital Universitario Quiron Salud, Madrid

66113

Caritasklinikum Saarbruecken St Theresia, Saarbrücken

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

Unknown

Flinders Medical Centre, Bedford Park

Peninsula and Southeast Oncology - Frankston Private Hospital, Frankston

Institut BERGONIE Centre de Lutte Contre le Cancer, Bordeaux

Centre GEORGES FRANÇOIS LECLERC, Dijon

Chu La Miletrie, Poitiers

Centre PAUL STRAUSS, Strasbourg

University Hospital Dresden, Dresden

Mav Korhaz Es Kozponti Rendelointezet, Budapest

Semmelweis Egyetem, Budapest

Clinexpert Kft Fázis I. Vizsgálóhely, Gyöngyös

AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna, Bologna

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola

Instituto Europeo di Oncologia, Milan

Azienda Ospedaliero Universitaria Modena, Modena

Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Torrette

Ospedale Borgo Roma, Verona

Hospital Senhora Da Oliveira - Hso-Epe, Guimarães

Centro Hospitalar Lisboa Norte - Hospital de Santa Maria, Lisbon

Fundacao Champalimaud, Lisbon

Chuac Hospital Teresa Herrera, A Coruña

Hospital Universitario de Badajoz, Badajoz

Hospital Universitario Vall D Hebron, Barcelona

Instituto Oncologico Dr Rosell Lor, Barcelona

Hospital Universitari de Lleida Arnaud de Villanova, Lleida

Hospital General Universitario Gregorio Marañon, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario La Paz, Madrid

Md Anserson Cancer Center, Madrid

Clinica Universidad de Navarra, Pamplona

Hospital Universitario Marques de Valdecilla, Santander

Complejo Hospitalario Universitario de Santiago de Compostela -Chus, Santiago de Compostela

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT05383352 - A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas | Biotech Hunter | Biotech Hunter